JPH06501262A - 新規な製法 - Google Patents
新規な製法Info
- Publication number
- JPH06501262A JPH06501262A JP3516242A JP51624291A JPH06501262A JP H06501262 A JPH06501262 A JP H06501262A JP 3516242 A JP3516242 A JP 3516242A JP 51624291 A JP51624291 A JP 51624291A JP H06501262 A JPH06501262 A JP H06501262A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- tables
- formulas
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000022244 formylation Effects 0.000 claims description 8
- 238000006170 formylation reaction Methods 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 238000006722 reduction reaction Methods 0.000 claims description 5
- 239000007868 Raney catalyst Substances 0.000 claims description 4
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000007039 two-step reaction Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 derivatives thereof Chemical class 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229960000193 formoterol fumarate Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- MOGUBMMGIJLRHQ-UHFFFAOYSA-N 2-(3-nitro-4-phenylmethoxyphenyl)oxirane Chemical compound [O-][N+](=O)C1=CC(C2OC2)=CC=C1OCC1=CC=CC=C1 MOGUBMMGIJLRHQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000001729 Ammonium fumarate Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000019297 ammonium fumarate Nutrition 0.000 description 2
- CKKXWJDFFQPBQL-SEPHDYHBSA-N azane;(e)-but-2-enedioic acid Chemical compound N.N.OC(=O)\C=C\C(O)=O CKKXWJDFFQPBQL-SEPHDYHBSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical class CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 1
- CVOKPUSIMWYQQA-UHFFFAOYSA-N acetic acid;chloroethane Chemical compound CCCl.CC(O)=O CVOKPUSIMWYQQA-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 1
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- CVGPWMGXKOKNFD-UHFFFAOYSA-N n-benzyl-1-(4-methoxyphenyl)propan-2-amine Chemical compound C1=CC(OC)=CC=C1CC(C)NCC1=CC=CC=C1 CVGPWMGXKOKNFD-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 208000024696 nocturnal asthma Diseases 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002217 thermospray mass spectrum Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims (9)
- 1.(a) ▲数式、化学式、表等があります▼II+▲数式、化学式、表等があります▼I IIを反応させて化合物1V ▲数式、化学式、表等があります▼IVを得、 (b)化合物IVを還元およびホルミル化して化合物V ▲数式、化学式、表等があります▼V を得、 (c)化合物Vのフマール酸塩を形成させそして結晶化によりラセミ体を分割し 、 (d)化合物Vの所望のラセミ体の塩基を抽出し(e)化合物Vの塩基の保護ベ ンジル基を水素化分解してAが▲数式、化学式、表等があります▼でありそして R1がHである化合物Iを得、そして任意的に (f)化合物Iのフマール酸塩および(または)溶媒和物を形成させそして任意 的に (g)Aが▲数式、化学式、表等があります▼(式中、RはHまたは1〜5個の 炭素原子を有する直鎖状または分枝鎖状のアルキル基でありそしてR2はHまた は1〜5個の炭素原子を有する直領伏または分枝鎖状のアルキル基である)また は▲数式、化学式、表等があります▼(式中、Rは1〜5個の炭素原子を有する 直鎖状または分枝鎖状のアルキル基である)でありそしてR1が上述した通りで ある場合は、工程(e)または(f)で得られた化合物をアルキル化することに よって、純粋なラセミ体または4つの異性体の混合物の形態の一般式I ▲数式、化学式、表等があります▼I 〔式中、R1はHまたは1〜5個の炭素原子を有する直鎖状または分枝鎖状のア ルキル基であり、Aは▲数式、化学式、表等があります▼(式中、RはHまたは 1〜5個の炭素原子を有する直鎖状または分枝鎖状のアルキル基でありそしてR 2はHまたは1〜5個の炭素原子の直鎖状または分枝鎖状のアルキル基である) または▲数式、化学式、表等があります▼(式中、Rは上述した通りである)で ある〕の化合物またはその医薬的に許容し得るフマール酸塩および(または)溶 媒和物の製法。
- 2.工程(a)を、低級アルコールのような溶剤の存在下において還流温度で、 または、溶剤の不存在下において好ましくは80〜120℃の温度で実施するこ とを特徴とする請求項1記載の方法。
- 3.工程(b)が、ラネ−ニッケル/ギ酸を使用する−工程の反応であるかまた はニトロ基を接触還元し次いで過剰のギ酸でホルミル化する二工程の反応である ことを特徴とする請求項1または2記載の方法。
- 4.工程(c)における結晶化によるラセミ体の分割を、酢酸エチル、酢酸イソ プロピルおよび(または)メチルイソブチルケトンからなる溶剤系中で実施する ことを特徴とする請求項1〜3の何れかの項記載の方法。
- 5.溶剤系が、さらにジメチルホルムアミド、ジメチルスルホキシドおよび(ま たは)メタノールのような請求項4に定義した溶剤よりもより極性の溶剤の小量 を含有することを特徴とする請求項4記載の方法。
- 6.好ましくはより極性の溶剤の量が15%より少ない量であることを特徴とす る請求項5記載の方法。
- 7.Rが水素でありそしてR1が水素であることを特徴とする請求項1〜6の何 れかの項記載の方法。
- 8.Rおよび(または)R2が1〜5個の炭素原子を有する直鎖状または分枝鎖 状のアルキル基であることを特徴とする請求項1〜6の何れかの項記載の方法。
- 9.純粋なラセミ体または4つの異性体の混合物の形態の一般式I ▲数式、化学式、表等があります▼I 〔式中、R1はHまたは1〜5個の炭素原子を有する直鎖状または分枝鎖状のア ルキル基であり、Aは▲数式、化学式、表等があります▼(式中、Rは1〜5個 の炭素原子を有する直鎖状または分枝鎖状のアルキル基でありそしてR2はHま たは1〜5個の炭素原子を有する直鎖状または分枝鎖状のアルキル基である)ま たは▲数式、化学式、表等があります▼(式中、Rは上述した通りである)であ る〕の化合物またはその医薬的に許容し得るフマール酸塩および(または)溶媒 和物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9003057-8 | 1990-09-26 | ||
| SE9003057A SE9003057D0 (sv) | 1990-09-26 | 1990-09-26 | New process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06501262A true JPH06501262A (ja) | 1994-02-10 |
| JP2801401B2 JP2801401B2 (ja) | 1998-09-21 |
Family
ID=20380456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3516242A Expired - Lifetime JP2801401B2 (ja) | 1990-09-26 | 1991-09-25 | 新規な製法 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0550612B1 (ja) |
| JP (1) | JP2801401B2 (ja) |
| KR (1) | KR0179639B1 (ja) |
| AT (1) | ATE134990T1 (ja) |
| AU (1) | AU652386B2 (ja) |
| BG (1) | BG61605B1 (ja) |
| CA (1) | CA2091343C (ja) |
| CZ (1) | CZ284256B6 (ja) |
| DE (1) | DE69117768T2 (ja) |
| DK (1) | DK0550612T3 (ja) |
| EE (1) | EE02979B1 (ja) |
| ES (1) | ES2084831T3 (ja) |
| FI (1) | FI111714B (ja) |
| GR (1) | GR3020134T3 (ja) |
| HK (1) | HK52297A (ja) |
| HU (1) | HU214054B (ja) |
| IE (1) | IE74387B1 (ja) |
| IS (1) | IS1684B (ja) |
| LT (1) | LT3813B (ja) |
| LV (1) | LV10770B (ja) |
| NO (1) | NO301709B1 (ja) |
| PL (1) | PL166434B1 (ja) |
| PT (1) | PT99051B (ja) |
| RU (1) | RU2079486C1 (ja) |
| SE (1) | SE9003057D0 (ja) |
| SG (1) | SG43150A1 (ja) |
| SK (1) | SK22793A3 (ja) |
| WO (1) | WO1992005147A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011501204A (ja) * | 2007-10-29 | 2011-01-06 | ジェネリクス・(ユーケー)・リミテッド | 新規なクロマトグラフィー方法 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| US6866839B2 (en) | 1991-04-05 | 2005-03-15 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| US5629200A (en) * | 1993-11-18 | 1997-05-13 | Daicel Chemical Industries, Ltd. | Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation |
| SE9404080L (sv) * | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| DK0938467T3 (da) * | 1996-11-11 | 2002-10-07 | Sepracor Inc | Fremgangsmåde til fremstilling af optisk rene isomerer af formoterol |
| US6303145B2 (en) | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| WO2002066027A1 (de) * | 2001-02-22 | 2002-08-29 | Universitätsklinikum Charite Medizinische Fakultät Der Humboldt-Universität Zu Berlin, Akademische Verwaltung - Forschung | Mittel zur hemmung von tumorzellen |
| US6472563B1 (en) | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| WO2008035380A2 (en) * | 2006-09-19 | 2008-03-27 | Natco Pharma Limited | An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| EA017627B1 (ru) | 2008-05-13 | 2013-01-30 | Астразенека Аб | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора |
| CN101921200B (zh) * | 2009-06-16 | 2014-01-15 | 上海医药工业研究院 | 一种n-苄基-1-(4-甲氧基苯基)-2-丙胺的制备方法 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| CN115368250B (zh) * | 2022-09-02 | 2024-07-26 | 博诺康源(北京)药业科技有限公司 | 拆分福莫特罗手性中间体的方法 |
| CN117682969A (zh) * | 2023-07-31 | 2024-03-12 | 浙江理工大学 | 一种福莫特罗中间体的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2305092A1 (de) | 1972-02-05 | 1973-08-16 | Yamanouchi Pharma Co Ltd | Alpha-aminomethylbenzylalkoholderivate |
| GB1468156A (en) * | 1973-07-19 | 1977-03-23 | Ici Ltd | Phenylethylamine derivatives |
| ES2005492A6 (es) | 1987-12-23 | 1989-03-01 | Lasa Lab | Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i). |
-
1990
- 1990-09-26 SE SE9003057A patent/SE9003057D0/xx unknown
-
1991
- 1991-09-25 HU HU9300867A patent/HU214054B/hu unknown
- 1991-09-25 PL PL91298237A patent/PL166434B1/pl unknown
- 1991-09-25 DK DK91917624.8T patent/DK0550612T3/da active
- 1991-09-25 CZ CZ93442A patent/CZ284256B6/cs not_active IP Right Cessation
- 1991-09-25 ES ES91917624T patent/ES2084831T3/es not_active Expired - Lifetime
- 1991-09-25 RU RU9193005269A patent/RU2079486C1/ru active
- 1991-09-25 AT AT91917624T patent/ATE134990T1/de not_active IP Right Cessation
- 1991-09-25 SK SK22793A patent/SK22793A3/sk unknown
- 1991-09-25 EP EP91917624A patent/EP0550612B1/en not_active Expired - Lifetime
- 1991-09-25 DE DE69117768T patent/DE69117768T2/de not_active Expired - Lifetime
- 1991-09-25 PT PT99051A patent/PT99051B/pt not_active IP Right Cessation
- 1991-09-25 IS IS3756A patent/IS1684B/is unknown
- 1991-09-25 KR KR1019930700901A patent/KR0179639B1/ko not_active Expired - Lifetime
- 1991-09-25 SG SG1996004479A patent/SG43150A1/en unknown
- 1991-09-25 CA CA002091343A patent/CA2091343C/en not_active Expired - Lifetime
- 1991-09-25 WO PCT/SE1991/000643 patent/WO1992005147A1/en not_active Ceased
- 1991-09-25 AU AU86520/91A patent/AU652386B2/en not_active Expired
- 1991-09-25 JP JP3516242A patent/JP2801401B2/ja not_active Expired - Lifetime
- 1991-09-26 IE IE337391A patent/IE74387B1/en not_active IP Right Cessation
-
1993
- 1993-03-23 NO NO931058A patent/NO301709B1/no not_active IP Right Cessation
- 1993-03-24 BG BG97576A patent/BG61605B1/bg unknown
- 1993-03-25 FI FI931333A patent/FI111714B/fi not_active IP Right Cessation
- 1993-08-10 LV LVP-93-1025A patent/LV10770B/en unknown
- 1993-12-30 LT LTIP1715A patent/LT3813B/lt not_active IP Right Cessation
-
1994
- 1994-11-23 EE EE9400425A patent/EE02979B1/xx unknown
-
1996
- 1996-05-31 GR GR960401514T patent/GR3020134T3/el unknown
-
1997
- 1997-04-24 HK HK52297A patent/HK52297A/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011501204A (ja) * | 2007-10-29 | 2011-01-06 | ジェネリクス・(ユーケー)・リミテッド | 新規なクロマトグラフィー方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06501262A (ja) | 新規な製法 | |
| US5434304A (en) | Process for preparing formoterol and related compounds | |
| US5545745A (en) | Enantioselective preparation of optically pure albuterol | |
| DE1543374C3 (de) | 3,4 Dihydroxyphenylalkanolamine und ihre Saureadditionssalze, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen | |
| EP0579681B1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| CN113999134B (zh) | 一种福莫特罗、其可药用盐及其中间体的制备方法 | |
| EP0103497A1 (fr) | Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| JPH02193951A (ja) | フルオキセチン類似体 | |
| DE69401177T2 (de) | 1-Aryloxy-3-alkylamino-2 propanol nitrat Ester, ihre Anwendung und korrespondierende pharmazeutische Zusammensetzungen | |
| JP2766728B2 (ja) | プロピルアミン誘導体 | |
| JP2852681B2 (ja) | 2―アミノ―7―ヒドロキシテトラリンカルボキシアルキルエーテル類およびその製造方法 | |
| JPS606668A (ja) | 置換されたアシルピペラジノキナゾリン,その製造方法及びそれを含む製薬組成物 | |
| EP0687252A1 (fr) | Derives de la phenoxy-2 ethylamine, leur preparation et leur application en therapeutique | |
| JPH0341459B2 (ja) | ||
| JP2825608B2 (ja) | 光学活性トレオ―3―アミノ―2―ヒドロキシペンタン酸及びその製造法 | |
| JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
| JPS5931493B2 (ja) | カテコ−ル誘導体 | |
| JPS58126845A (ja) | プロパノ−ル誘導体の製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070710 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080710 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080710 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090710 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090710 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100710 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110710 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110710 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120710 Year of fee payment: 14 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120710 Year of fee payment: 14 |